𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

✍ Scribed by Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. Smyth; Ian W. B. Grant; Graham K. Crompton

Publisher
Springer
Year
1984
Tongue
English
Weight
320 KB
Volume
13
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in patients with limited and extensive disease, respectively. Time to relapse was short in those responding (4-4.5 months), and most responders required additional treatments. The overall toxicity was minimal and patient compliance was high. This combination is useful for the palliative treatment of small cell lung cancer when aggressive chemotherapy is inappropriate.

πŸ“œ SIMILAR VOLUMES

Phase-II study of vindesine and hexameth
Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung
✍ Rudolf A. Joss; Jean-Paul Obrecht; Walter F. Jungi; Pierre Alberto; Christian Sa πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 163 KB

Twenty-five patients with measurable small cell lung cancer relapsing after first-line chemotherapy were treated with vindesine 3 mg/m2 IV on days 1 and 8 and hexamethylmelamine 100 mg/m2 PO on days 1-14, repeated every 3 weeks. Among 18 fully evaluable patients there was 1 partial remission lasting

Phase II trial of esorubicin (4β€²deoxydox
Phase II trial of esorubicin (4β€²deoxydoxorubicin, DxDx) in patients with small cell lung cancer
✍ James R. Rigas; Mark G. Kris; Richard J. Gralla; Robert T. Heelan; Linda D. Mark πŸ“‚ Article πŸ“… 1991 πŸ› Springer US 🌐 English βš– 264 KB

Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m 2 intravenously) every 3 we